Skip to main content

Advertisement

SpringerLink
Log in

Clinical Impact of p27Kip1 and CaSR Expression on Primary Hyperparathyroidism

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

We aimed to investigate the expressions of p27 kinase inhibitory protein 1 (p27Kip1) and calcium sensing receptor (CaSR) in adenomas and normal parathyroid tissue and to evaluate the relationship of these molecules with clinical and biochemical parameters in primary hyperparathyroidism (PHPT). Fifty-one patients with histopathologically confirmed parathyroid adenomas and 20 patients with normal parathyroid glands (which were removed incidentally during thyroid resection) were included. Immunohistochemical stainings of CaSR and p27Kip1 were performed in surgical specimens. Clinical features, biochemical parameters, and BMD measurements of patients with PHPT were evaluated retrospectively. Expressions of p27Kip1 and CaSR were decreased in parathyroid adenomas, compared to normal glands (p < 0.05). High intensity of CaSR staining (3+) was more frequent in normal parathyroid tissue (75%) than adenomas (12%) (p < 0.01). Hypertension was not observed in patients with high staining intensity of CaSR (p = 0.032). There was a negative association between CaSR expression and body mass index (BMI) (p = 0.027, r = − 0.313). There was no significant relationship between p27Kip1 and CaSR expressions, serum calcium, plasma parathormone, 25-hydroxy vitamin D levels, and bone density (p > 0.05). The expressions of p27Kip1 and CaSR were decreased in PHPT patients. This reduction may play an important role in the pathogenesis of PHPT. However, neither p27Kip1 nor CaSR expression was found to be useful in predicting prognosis or severity of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171–177.

    Article  PubMed  Google Scholar 

  2. Costa-Guda J, Arnold A. Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors. Mol Cell Endocrinol. 2014;386(1–2):46–54.

    Article  PubMed  CAS  Google Scholar 

  3. Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet. 1997;16(4):375–378.

    Article  PubMed  CAS  Google Scholar 

  4. Bjorklund P, Lindberg D, Akerstrom G, Westin G. Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer. 2008;7:53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Soong CP, Arnold A. Recurrent ZFX mutations in human sporadic parathyroid adenomas. Oncoscience. 2014;1(5):360–366.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol. 1997;150(2):401–407.

    PubMed  PubMed Central  CAS  Google Scholar 

  7. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol. 1999;23(3):288–295.

    Article  PubMed  CAS  Google Scholar 

  8. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol. 2003;148(4):403–411.

    Article  PubMed  CAS  Google Scholar 

  9. Filopanti M, Corbetta S, Barbieri AM, Spada A. Pharmacology of the calcium sensing receptor. Clin Cases Miner Bone Metab. 2013;10(3):162–165.

    PubMed  Google Scholar 

  10. Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. Front Horm Res. 2013;41:63–78.

    Article  PubMed  CAS  Google Scholar 

  11. Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2011;96(4):E701–E706.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.

  13. Hemmer S, Wasenius VM, Haglund C, Zhu Y, Knuutila S, Franssila K, et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol. 2001;158(4):1355–1362.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81(5):1736–1739.

    PubMed  CAS  Google Scholar 

  15. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem. 2002;277(33):30337–30350.

    Article  PubMed  CAS  Google Scholar 

  16. Varshney S, Bhadada SK, Saikia UN, Sachdeva N, Behera A, Arya AK, et al. Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur J Endocrinol. 2013;169(1):109–116.

    Article  PubMed  CAS  Google Scholar 

  17. Canaff L, Zhou X, Hendy GN. The proinflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Stat1/3 and Sp1/3. J Biol Chem. 2008;283(20):13586–13600.

    Article  PubMed  CAS  Google Scholar 

  18. Canaff L, Hendy GN. Calcium-sensing receptor gene transcription is up-regulated by the proinflammatory cytokine, interleukin-1beta. Role of the NF-kappaB PATHWAY and kappaB elements. J Biol Chem. 2005;280(14):14177–14188.

    Article  PubMed  CAS  Google Scholar 

  19. Zhai TY, Cui BH, Zou L, Zeng JY, Gao S, Zhao Q, et al. Expression and Role of the Calcium-Sensing Receptor in Rat Peripheral Blood Polymorphonuclear Neutrophils. Oxid Med Cell Longev. 2017;2017:3869561.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90(3):1525–1530.

    Article  PubMed  CAS  Google Scholar 

  21. Al-Daghri NM, Al-Attas OS, Alkharfy KM, Khan N, Mohammed AK, Vinodson B, et al. Association of VDR-gene variants with factors related to the metabolic syndrome, type 2 diabetes and vitamin D deficiency. Gene. 2014;542(2):129–133.

    Article  PubMed  CAS  Google Scholar 

  22. Cifuentes M, Fuentes C, Tobar N, Acevedo I, Villalobos E, Hugo E, et al. Calcium sensing receptor activation elevates proinflammatory factor expression in human adipose cells and adipose tissue. Mol Cell Endocrinol. 2012;361(1–2):24–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Cifuentes M, Fuentes C, Mattar P, Tobar N, Hugo E, Ben-Jonathan N, et al. Obesity-associated proinflammatory cytokines increase calcium sensing receptor (CaSR) protein expression in primary human adipocytes and LS14 human adipose cell line. Arch Biochem Biophys. 2010;500(2):151–156.

    Article  PubMed  CAS  Google Scholar 

  24. Atchison DK, Harding P, Beierwaltes WH. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension. 2011;58(4):604–610.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Atchison DK, Beierwaltes WH. The influence of extracellular and intracellular calcium on the secretion of renin. Pflugers Arch. 2013;465(1):59–69.

    Article  PubMed  CAS  Google Scholar 

  26. Chen S, Glenn DJ, Ni W, Grigsby CL, Olsen K, Nishimoto M, et al. Expression of the vitamin d receptor is increased in the hypertrophic heart. Hypertension. 2008;52(6):1106–1112.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89-90(1–5):387–392.

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This study was supported financially by Ankara University Foundation of Medicine.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Ankara University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey

    Gozde Sengul Aycicek

  2. Department of Endocrinology and Metabolism, Ankara University Faculty of Medicine, Ankara, Turkey

    Berna Imge Aydogan, Mustafa Sahin & Nilgun Baskal

  3. Department of Pathology, Ankara University Faculty of Medicine, Ankara, Turkey

    Cevriye Cansız Ersoz & Serpil Dizbay Sak

Authors
  1. Gozde Sengul Aycicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Berna Imge Aydogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mustafa Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cevriye Cansız Ersoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Serpil Dizbay Sak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nilgun Baskal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gozde Sengul Aycicek.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

For this type of study, formal consent is not required.

Disclosure Statement

The authors have nothing to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sengul Aycicek, G., Aydogan, B.I., Sahin, M. et al. Clinical Impact of p27Kip1 and CaSR Expression on Primary Hyperparathyroidism. Endocr Pathol 29, 250–258 (2018). https://doi.org/10.1007/s12022-018-9524-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-018-9524-9

Keywords

Search

Navigation